Dr. Yevgeniy Veltman, MD

Dr. Veltman practices at Golden Gate Urology Inc in San Francisco, California.

Dr. Veltman's NPI, 1497917579, was assigned on June 30, 2008. Dr. Veltman graduated from University of Miami, Miller School of Medicine in 2008. Dr. Veltman holds California license A124270.

Dr. Veltman's primary practice is Golden Gate Urology Inc, at 2186 Geary Blvd, San Francisco, CA 94115 in San Francisco County. The practice phone is (415) 543-2830.

Dr. Veltman's primary practice is Golden Gate Urology Inc in San Francisco, California. Dr. Veltman is also affiliated with UCSF Helen Diller Medical Center at Parnassus Heights. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Veltman to 4 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Veltman practices, 9 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Veltman's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Veltman is board certified in urology by the American Board of Urology. Dmand AI has Dr. Veltman's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney stone disease, prostate cancer, prostate inflammation or infection and urinary endoscopy among the conditions Dr. Veltman treats.

CMS data shows 4,164 Medicare services from Dr. Veltman across 17 procedure codes in 2024, for 717 Medicare patients. Medicare paid $227,657 for them.

CMS counts 717 Medicare patients who saw Dr. Veltman in 2024. The largest group is 65 to 74, with 317 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.91, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Veltman's median patient age at 73, with 12% women.

In 2024, Dr. Veltman wrote 4,135 Medicare Part D claims for 829 patients. 92% of them were for generic drugs. CMS names the drug for 4,042 of them, across 17 drugs with 11 or more claims each, at $366,572 in total drug cost. In 2023, CMS named 4,234 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Veltman for performance year 2024, reported as part of a group. Dr. Veltman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Veltman as offering telehealth.

Dmand AI links 1 paper to Dr. Veltman. Dr. Veltman's most frequent co-authors are Louis R. Pizano, MD, Christopher Robert Seaver, MD and David V. Shatz, MD.

CMS Open Payments shows 474 general payments to Dr. Veltman from 41 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 99% of the total. Sumitomo Pharma America, Inc. paid the most, $2,311.

Dmand AI lists 2 awards for Dr. Veltman, most recently ACS Fellow in 2013.

Dr. Veltman graduated from University of Miami, Miller School of Medicine in 2008. Dr. Veltman is a member of ACS.

Dr. Veltman is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.